HCV-Associated Cryoglobulinemic Vasculitis With Active Nephritis: Antiviral First, or Rituximab First
A single patient with newly active renal involvement from longstanding, untreated hepatitis C. The disagreement is whether treating the viral driver first is still the right sequence once the vasculitis has become organ-threatening.
Maria C. has known she has hepatitis C for years — diagnosed incidentally on a blood donation screen she still remembers being surprised by — but had never treated it, partly because she felt fine and partly because the referral kept getting deprioritized against more pressing things. The palpable purpura on both lower legs that brought her in three weeks ago felt like a new, unrelated problem, joined soon after by joint pain in her hands and, on the labwork her primary care doctor ordered to investigate, a creatinine that had climbed from a baseline 0.8 to 1.6 with an actively abnormal urine sediment — dysmorphic red cells, real proteinuria. Cryoglobulins came back positive, type II mixed, with a C4 low enough to leave little doubt: her untreated hepatitis C had finally produced the organ-threatening complication her deprioritized referral had, in effect, been gambling against.
Direct-acting antivirals have genuinely changed the calculus for HCV-associated cryoglobulinemic vasculitis — treating the viral driver now routinely achieves both sustained virologic response and immunologic remission of the vasculitis in a majority of patients, without needing immunosuppression at all, a real shift from the interferon era's much harder tradeoffs. That's the strongest argument for treating the virus first. But her renal involvement is already active and worsening — creatinine doubling in three weeks with an inflamed urine sediment isn't a stable, low-grade presentation, and DAA therapy takes weeks to achieve sustained virologic response, time during which untreated active glomerulonephritis can do real, occasionally irreversible damage. KDIGO's 2022 guideline on hepatitis C in chronic kidney disease names this severity as the threshold for adding immunosuppression — rituximab first-line — alongside, not after, the antiviral, since B-cell depletion removes the clones producing the pathogenic cryoglobulin without waiting on viral clearance. What complicates borrowing that recommendation wholesale is who the trials behind it actually enrolled. Both randomized trials of rituximab here — De Vita's 59 patients, where treatment survival at twelve months ran 64.3 percent against 3.5 percent on conventional therapy, and Sneller's smaller trial, where remission at six months ran 83 percent against 8 percent — restricted enrollment to patients in whom antiviral therapy had already failed or was not indicated. Maria has never been treated for her hepatitis C at all. The drug's effect on her vasculitis has no obvious reason to differ, but she is not in either studied population, and the sequencing question those trials never had to face is the one actually in front of the room.
On the joint hepatology-nephrology-rheumatology consult
Direct-acting antivirals have changed this disease. Treating the HCV directly now routinely achieves both viral cure and immunologic remission of the vasculitis in a majority of patients, without ever needing immunosuppression. I'd start DAA therapy and add rituximab only if her renal function keeps declining despite that.
I agree DAA therapy is the right eventual treatment for the driver, but her creatinine has nearly doubled in three weeks with an actively inflamed urine sediment — that's not a stable presentation we can afford to wait on. KDIGO's 2022 hepatitis C in CKD guideline uses exactly this severity as the threshold for starting immunosuppression upfront — rituximab first-line, with the antiviral, not after it. I'd start rituximab now, alongside DAA, not instead of it.
Waiting to see if her renal function keeps declining before adding rituximab means using her kidney function as the test — by the time we have that answer, the damage the test was meant to avoid may have already happened.
I agree with starting rituximab now, and I'd start the DAA with it rather than after — that is what KDIGO actually says, and I don't have evidence for a deferral. What I'd add is a caution about how confident we let ourselves be. De Vita and Sneller both enrolled patients whose antiviral therapy had already failed or was contraindicated. She has never been treated. We are extrapolating the rituximab effect into a population neither trial studied, and the direction of that extrapolation isn't obvious: an untreated viral driver is still actively producing the antigenic stimulus, which could cut either way once B cells begin returning.
So: both now, but with the reassessment written down rather than assumed. Creatinine and sediment at two weeks, cryocrit and C4 at four, and an explicit plan for what happens if she is one of the patients whose vasculitis flares as B cells repopulate before sustained virologic response is reached — the failure mode her being antiviral-naive makes more plausible than it would be in either trial's population.
Agreed: start rituximab and direct-acting antiviral therapy together, per KDIGO 2022, rather than sequencing them. Creatinine and urine sediment rechecked at two weeks, cryocrit and C4 at four.
The DAA-first position's underlying premise — that treating the virus is the more durable long-term fix — was not disputed by anyone; what it lost was the claim that the antiviral timeline alone is fast enough for a kidney already losing function. Left unresolved rather than smoothed over: how much confidence the rituximab evidence actually earns here. Both randomized trials enrolled patients whose antiviral therapy had already failed, and she has never been treated, so the plan carries an explicit reassessment point for a flare as B cells repopulate — a failure mode her being antiviral-naive makes more plausible than either trial had occasion to measure.